| REVIEW |
|
|
|
|
|
Natural approaches for the management of ulcerative colitis: evidence of preclinical and clinical investigations |
| Rudra Narayan Subudhi, Neelam Poonia, Dilpreet Singh, Vimal Arora |
| Department of Pharmaceutics, University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali, Punjab, India |
|
|
|
|
Abstract Ulcerative colitis (UC) is a recurring autoimmune disorder characterized by persistent inflammation in the mucosal lining of the lower part of the large intestine. Conventional treatment options such as salicylates, corticosteroids, and immunosuppressants often come with severe side effects, limited bioavailability, and the development of drug resistance, which hampers their therapeutic effectiveness. Therefore, it is imperative to explore natural strategies as safe and alternative treatments for UC. Currently, around 40% of UC patients find relief through natural constituents, which can help reduce toxic side effects and maintain clinical remission. This review aims to provide a summary of both preclinical and clinical evidence supporting the efficacy of various natural substances in the prophylaxis of UC. These natural options include plant extracts, essential oils, nutraceuticals, and phytochemicals. Furthermore, we will delve into the potential mechanisms that underlie the protective and curative actions of these novel herbal agents. In summary, this review will explore the effectiveness of natural remedies for UC, shedding light on their preclinical and clinical findings and the mechanisms behind their therapeutic actions. These alternatives offer hope for improved treatment outcomes and reduced side effects for individuals suffering from this challenging autoimmune condition.
|
| Keywords
Ulcerative colitis
Pathophysiology
Plant extracts
Essential oils
Nutraceuticals
Phytocompounds
|
|
Corresponding Authors:
Neelam Poonia,E-mail:neelampoonia123@gmail.com
E-mail: neelampoonia123@gmail.com
|
|
Issue Date: 14 October 2024
|
|
|
[1] Buie MJ, Quan J, Windsor JW, Coward S, Hansen TM, King JA, Kotze PG, Gearry RB, Ng SC, Mak JW, Abreu MT. Global hospitalization trends for Crohn’s disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses. Clin Gastroenterol Hepatol. 2023;21(9):2211-21. https://doi.org/10.1016/j.cgh.2022.06.030.
[2] Wei SC, Sollano J, Hui YT, Yu W, Santos Estrella PV, Llamado LJ, Koram N. Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia. Expert Rev Gastroenterol Hepatol. 2021;15(3):275-89. https://doi.org/10.1080/17474124.2021.1840976.
[3] Aniwan S, Santiago P, Loftus EV Jr, Park SH. The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries. United Eur Gastroenterol J. 2022;10(10):1063-76. https://doi.org/10.1002/ueg2.12350.
[4] Lewis JD, Parlett LE, Funk ML, Brensinger C, Pate V, Wu Q, Dawwas GK, Weiss A, Constant BD, McCauley M, Haynes K. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology. 2023;165(5):1197-205. https://doi.org/10.1053/j.gastro.2023.07.003.
[5] Weber F, Eger KI, March C, Croner RS, Meyer F. Manifestation of acute appendicitis as known but paradox visceral side effect of ulcerative colitis anti-inflammatory therapy with januskinase-inhibitor Tofacitinib (XeljanzTM). Pathol Res Pract. 2023;248: 154333. https://doi.org/10.1016/j.prp.2023.154333.
[6] Gros B, Kaplan GG. Ulcerative colitis in adults: a review. JAMA. 2023;330(10):951-65. https://doi.org/10.1001/jama.2023.15389.
[7] Sandborn WJ, Danese S, Leszczyszyn J, Romatowski J, Altintas E, Peeva E, Hassan-Zahraee M, Vincent MS, Reddy PS, Banfield C, Salganik M. Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study. Clin Gastroenterol Hepatol. 2023. https://doi.org/10.1016/j.cgh.2022.12.029.
[8] Lim J, Rezaie A. Irritable bowel syndrome-like symptoms in quiescent inflammatory bowel disease: a practical approach to diagnosis and treatment of organic causes. Dig Dis Sci. 2023;68(11):4081-97. https://doi.org/10.1007/s10620-023-08095-w.
[9] Singh S, Dulai PS. Ulcerative colitis: clinical manifestations and management. Yamada's Textbook of Gastroenterology. 2022:1248-93.https://doi.org/10.1002/9781118512104.ch28
[10] Kotze PG, Heuthorst L, Lightner AL, Damião AO, Bemelman WA. New insights on the surgical management of ulcerative colitis in the 21st century. Lancet Gastroenterol Hepatol. 2022. https://doi.org/10.1016/S2468-1253(22)00001-2.
[11] Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W, Eder P. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2-17. https://doi.org/10.1093/ecco-jcc/jjab178.
[12] Guo XY, Liu XJ, Hao JY. Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment. J Dig Dis. 2020;21(3):147-59. https://doi.org/10.1111/1751-2980.12849.
[13] Amiot A, Bouguen G, Bonnaud G, Bouhnik Y, Hagege H, Peyrin-Biroulet L, Abitbol V, Malamut G, Amiot A, Boruchowicz A, Siproudhis L. Clinical guidelines for the management of inflammatory bowel disease: update of a French national consensus. Dig Liver Dis. 2021;53(1):35-43. https://doi.org/10.1016/j.dld.2020.10.018.
[14] Liu S, Eisenstein S. State-of-the-art surgery for ulcerative colitis. Langenbeck’s Arch Surg. 2021;406(6):1751-61. https://doi.org/10.1007/s00423-021-02295-6.
[15] Lu L, Dong J, Liu Y, Qian Y, Zhang G, Zhou W, Zhao A, Ji G, Xu H. New insights into natural products that target the gut microbiota: effects on the prevention and treatment of colorectal cancer. Front Pharmacol. 2022;13: 964793. https://doi.org/10.3389/fphar.2022.964793.
[16] Salibay CC, Mahboob T, Verma AK, San Sebastian JS, Tabo HA, Raju CS, Nissapatorn V. Natural product-derived drugs for the treatment of inflammatory bowel diseases (IBD). Inflamm Nat Prod. 2021. https://doi.org/10.5217/ir.2014.12.2.103.
[17] Xue JC, Yuan S, Meng H, Hou XT, Li J, Zhang HM, Chen LL, Zhang CH, Zhang QG. The role and mechanism of flavonoid herbal natural products in ulcerative colitis. Biomed Pharmacother. 2023;158: 114086. https://doi.org/10.1016/j.biopha.2022.114086.
[18] Duan L, Cheng S, Li L, Liu Y, Wang D, Liu G. Natural anti-inflammatory compounds as drug candidates for inflammatory bowel disease. Front Pharmacol. 2021;14(12): 684486. https://doi.org/10.3389/fphar.2021.684486.
[19] Akkol EK, Karpuz B, Sobarzo-Sánchez E, Khan H. A phytopharmacological overview of medicinal plants used for prophylactic and treatment of colitis. Food Chem Toxicol. 2020;144: 111628. https://doi.org/10.1016/j.fct.2020.111628.
[20] Dunleavy KA, Raffals LE, Camilleri M. Intestinal barrier dysfunction in inflammatory bowel disease: underpinning pathogenesis and therapeutics. Digest Dis Sci. 2023;68(12):4306-20. https://doi.org/10.1007/s10620-023-08122-w.
[21] Liu Z, Zhang Y, Jin T, Yi C, Ocansey DK, Mao F. The role of NOD2 in intestinal immune response and microbiota modulation: a therapeutic target in inflammatory bowel disease. Int Immunopharmacol. 2022;113: 109466. https://doi.org/10.1016/j.intimp.2022.109466.
[22] Fu Q, Song T, Ma X, Cui J. Research progress on the relationship between intestinal microecology and intestinal bowel disease. Anim Models Exp Med. 2022;5(4):297-310. https://doi.org/10.1002/ame2.12262.
[23] Chu J, Feng S, Guo C, Xue B, He K, Li L. Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: s review. Biomed Pharmacother. 2023;164: 114985. https://doi.org/10.1016/j.biopha.2023.114985.
[24] Mahapatro M, Erkert L, Becker C. Cytokine-mediated crosstalk between immune cells and epithelial cells in the gut. Cells. 2021;10(1):111. https://doi.org/10.3390/cells10010111.
[25] Nakase H, Sato N, Mizuno N, Ikawa Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmunity Rev. 2022;21(3): 103017. https://doi.org/10.1016/j.autrev.2021.103017.
[26] Du L, Ha C. Epidemiology and pathogenesis of ulcerative colitis. Gastroenterol Clin. 2020;49(4):643-54. https://doi.org/10.1016/j.gtc.2020.07.005.
[27] Kaur A, Goggolidou P. Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies. J Inflamm. 2020;17:1-8. https://doi.org/10.1186/s12950-020-00246-4.
[28] Kałużna A, Olczyk P, Komosińska-Vassev K. The role of innate and adaptive immune cells in the pathogenesis and development of the inflammatory response in ulcerative colitis. J Clin Med. 2022;11(2):400. https://doi.org/10.3390/jcm11020400.
[29] Gomez-Bris R, Saez A, Herrero-Fernandez B, Rius C, Sanchez-Martinez H, Gonzalez-Granado JM. CD4 T-cell subsets and the pathophysiology of inflammatory bowel disease. Int J Mol Sci. 2023;24(3):2696. https://doi.org/10.3390/ijms24032696.
[30] Tindemans I, Joosse ME, Samsom JN. Dissecting the heterogeneity in T-cell mediated inflammation in IBD. Cells. 2020;9(1):110. https://doi.org/10.3390/cells9010110.
[31] Lu Q, Yang MF, Liang YJ, Xu J, Xu HM, Nie YQ, Wang LS, Yao J, Li DF. Immunology of inflammatory bowel disease: molecular mechanisms and therapeutics. J Inflamm Res. 2022;15:1825-44. https://doi.org/10.2147/JIR.S353038.
[32] Moreira Lopes TC, Mosser DM, Gonçalves R. Macrophage polarization in intestinal inflammation and gut homeostasis. Inflamm Res. 2020;69:1163-72. https://doi.org/10.1007/s00011-020-01398-y.
[33] Yip JL, Balasuriya GK, Spencer SJ, Hill-Yardin EL. The role of intestinal macrophages in gastrointestinal homeostasis: heterogeneity and implications in disease. Cell Mol Gastroenterol Hepatol. 2021;12(5):1701-18. https://doi.org/10.1016/j.jcmgh.2021.08.021.
[34] Xiang C, Liu M, Lu Q, Fan C, Lu H, Feng C, Yang X, Li H, Tang W. Blockade of TLRs-triggered macrophage activation by caffeic acid exerted protective effects on experimental ulcerative colitis. Cell Immunol. 2021;365: 104364. https://doi.org/10.1016/j.cellimm.2021.104364.
[35] Dharmasiri S, Garrido-Martin EM, Harris RJ, Bateman AC, Collins JE, Cummings JF, Sanchez-Elsner T. Human intestinal macrophages are involved in the pathology of both ulcerative colitis and Crohn disease. Inflamm Bowel Dis. 2021;27(10):1641-52. https://doi.org/10.1093/ibd/izab029.
[36] Gohil S, Majd Z, Sheneman JC, Abughosh SM. Interventions to improve medication adherence in inflammatory bowel disease: a systematic review. Patient Educ Counsel. 2022;105(7):1731-42. https://doi.org/10.1016/j.pec.2021.10.017.
[37] Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65(12): 100851. https://doi.org/10.1016/j.disamonth.2019.02.004.
[38] Smith RL, Taylor KM, Friedman AB, Gibson RN, Gibson PR. Systematic review: clinical utility of gastrointestinal ultrasound in the diagnosis, assessment and management of patients with ulcerative colitis. J Crohns Colitis. 2020;14(4):465-79. https://doi.org/10.1093/ecco-jcc/jjz163.
[39] Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative colitis—diagnostic and therapeutic algorithms. Dtsch Arztebl Int. 2020;117(33-34):564. https://doi.org/10.3238/arztebl.2020.0564.
[40] Axelrad JE, Olén O, Askling J, Lebwohl B, Khalili H, Sachs MC, Ludvigsson JF. Gastrointestinal infection increases odds of inflammatory bowel disease in a nationwide case-control study. Clin Gastroenterol Hepatol. 2019;17(7):1311-22. https://doi.org/10.1016/j.cgh.2018.09.034.
[41] Frickenstein AN, Jones MA, Behkam B, McNally LR. Imaging inflammation and infection in the gastrointestinal tract. Int J Mol Sci. 2019;21(1):243. https://doi.org/10.3390/ijms21010243.
[42] Takenaka K, Fujii T, Kawamoto A, Suzuki K, Shimizu H, Maeyashiki C, Yamaji O, Motobayashi M, Igarashi A, Hanazawa R, Hibiya S. Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study. Lancet Gastroenterol Hepatol. 2022;7(3):230-7. https://doi.org/10.1016/S2468-1253(21)00372-1.
[43] Mokter MF, Oh J, Tavanapong W, Wong J, de Groen PC. Classification of ulcerative colitis severity in colonoscopy videos using vascular pattern detection. InMachine Learning in Medical Imaging: 11th International Workshop, MLMI 2020, Held in Conjunction with MICCAI 2020, Lima, Peru, October 4, 2020, Proceedings 11 2020 (pp. 552-562). Springer International Publishing. https://doi.org/10.1007/978-3-030-59861-7_56
[44] Linggi B, Jairath V, Zou G, Shackelton LM, McGovern DP, Salas A, Verstockt B, Silverberg MS, Nayeri S, Feagan BG, van de Casteele N. Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis. Sci Rep. 2021;11(1):18243. https://doi.org/10.1038/s41598-021-97366-5.
[45] Battat R, Vande Casteele N, Pai RK, Wang Z, Zou G, McDonald JW, Duijvestein M, Jeyarajah J, Parker CE, Van Viegen T, Nelson SA. Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. Aliment Pharmacol Ther. 2020;52(10):1574-82. https://doi.org/10.1111/apt.16083.
[46] Park SB, Kim SJ, Lee J, Lee YJ, Baek DH, Seo GS, Kim ES, Kim SW, Kim SY. Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis. BMC Gastroenterol. 2022;22(1):1-7. https://doi.org/10.1186/s12876-022-02178-0.
[47] Chen H, Wu L, Wang M, Shao B, Ye L, Zhang Y, Cao Q. Use of the ulcerative colitis endoscopic index of severity and Mayo endoscopic score for predicting the therapeutic effect of mesalazine in patients with ulcerative colitis. Laparosc Endosc Robot Surg. 2021;4(2):33-9. https://doi.org/10.1016/j.lers.2021.04.003.
[48] Pagnini C, Di Paolo MC, Mariani BM, Urgesi R, Pallotta L, Vitale MA, Villotti G, d’Alba L, De Cesare MA, Di Giulio E, Graziani MG. Mayo endoscopic score and ulcerative colitis endoscopic index are equally effective for endoscopic activity evaluation in ulcerative colitis patients in a real-life setting. Gastroenterol Insights. 2021;12(2):217-24. https://doi.org/10.3390/gastroent12020019.
[49] Xiao BH, Ma XD, Lv JJ, Yang T, Liu XJ, An LY, Qi YX, Lu ML, Duan YQ, Sun DL. Systematic evaluation of the diagnostic approach of inflammatory bowel disease guidelines. Int J Clin Pract. 2021;75(10):14365. https://doi.org/10.1111/ijcp.14365.
[50] Shaban N, Hoad CL, Naim I, Alshammari M, Radford SJ, Clarke C, Marciani L, Moran G. Imaging in inflammatory bowel disease: current and future perspectives. Frontline Gastroenterol. 2022. https://doi.org/10.1136/flgastro-2022-102117.
[51] Le Berre C, Ananthakrishnan AN, Danese S, Singh S, Peyrin-Biroulet L. Ulcerative colitis and Crohn’s disease have similar burden and goals for treatment. Clin Gastroenterol Hepatol. 2020;18(1):14-23. https://doi.org/10.1016/j.cgh.2019.07.005.
[52] D’Amico F, Fasulo E, Jairath V, Paridaens K, Peyrin-Biroulet L, Danese S. Management and treatment optimization of patients with mild to moderate ulcerative colitis. Expert Rev Clin Immunol. 2023;13:1-4. https://doi.org/10.1080/1744666X.2023.2292768.
[53] Cai Z, Wang S, Li J. Treatment of inflammatory bowel disease: a comprehensive review. Front Med. 2021;8: 765474. https://doi.org/10.3389/fmed.2021.765474.
[54] Chen M, Lan H, Jin K, Chen Y. Responsive nanosystems for targeted therapy of ulcerative colitis: current practices and future perspectives. Drug Deliv. 2023;30(1):2219427. https://doi.org/10.1080/10717544.2023.2219427.
[55] Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S. An update on current pharmacotherapeutic options for the treatment of ulcerative colitis. J Clin Med. 2022;11(9):2302. https://doi.org/10.3390/jcm11092302.
[56] Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021;6(7):589-95. https://doi.org/10.1016/S2468-1253(21)00065-0.
[57] Gupta M, Mishra V, Gulati M, Kapoor B, Kaur A, Gupta R, Tambuwala MM. Natural compounds as safe therapeutic options for ulcerative colitis. Inflammopharmacology. 2022;30(2):397-434. https://doi.org/10.1007/s10787-022-00931-1.
[58] Moudgil KD, Venkatesha SH. The anti-inflammatory and immunomodulatory activities of natural products to control autoimmune inflammation. Int J Mol Sci. 2022;24(1):95. https://doi.org/10.3390/ijms24010095.
[59] El Menyiy N, El Allam A, Aboulaghras S, Jaouadi I, Bakrim S, El Omari N, Shariati MA, Miftakhutdinov A, Wilairatana P, Mubarak MS, Bouyahya A. Inflammatory auto-immune diseases of the intestine and their management by natural bioactive compounds. Biomed Pharmacother. 2022;1(151): 113158. https://doi.org/10.1016/j.biopha.2022.113158.
[60] Davila MM, Papada E. The role of plant-derived natural products in the management of inflammatory bowel disease—what is the clinical evidence so far? Life. 2023;13(8):1703. https://doi.org/10.1586/17474124.2016.1145546.
[61] Guo N, Lv LL. Mechanistic insights into the role of probiotics in modulating immune cells in ulcerative colitis. Immunity, Inflamm Dis. 2023;11(10): e1045. https://doi.org/10.1002/iid3.1045.
[62] Chang Y, Zhai L, Peng J, Wu H, Bian Z, Xiao H. Phytochemicals as regulators of Th17/Treg balance in inflammatory bowel diseases. Biomed Pharmacother. 2021;1(141): 111931. https://doi.org/10.1016/j.biopha.2021.111931.
[63] Chen L, Ruan G, Cheng Y, Yi A, Chen D, Wei Y. The role of Th17 cells in inflammatory bowel disease and the research progress. Front Immunol. 2023;9(13):1055914. https://doi.org/10.3389/fimmu.2022.1055914.
[64] Zhao J, Lu Q, Liu Y, Shi Z, Hu L, Zeng Z, Tu Y, Xiao Z, Xu Q. Th17 cells in inflammatory bowel disease: cytokines, plasticity, and therapies. J Immunol Res. 2021;22:2021. https://doi.org/10.1155/2021/8816041.
[65] Caioni G, Viscido A, Angelo M, Panella G, Castelli V, Merola C, Frieri G, Latella G, Cimini A, Benedetti E. Inflammatory bowel disease: new insights into the interplay between environmental factors and PPARγ. Int J Mol Sci. 2021;22(3):985. https://doi.org/10.3390/ijms22030985.
[66] Villarroel-Vicente C, Gutierrez-Palomo S, Ferri J, Cortes D, Cabedo N. Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: an overview. Eur J Med Chem. 2021;5(221): 113535. https://doi.org/10.1016/j.ejmech.2021.113535.
[67] Venkataraman B, Ojha S, Belur PD, Bhongade B, Raj V, Collin PD, Adrian TE, Subramanya SB. Phytochemical drug candidates for the modulation of peroxisome proliferator-activated receptor γ in inflammatory bowel diseases. Phytother Res. 2020;34(7):1530-49. https://doi.org/10.1002/ptr.6625.
[68] Laurindo LF, de Maio MC, Minniti G, de Góes CN, Barbalho SM, Quesada K, Guiguer EL, Sloan KP, Detregiachi CR, Araújo AC, de Alvares GR. Effects of medicinal plants and phytochemicals in Nrf2 pathways during inflammatory bowel diseases and related colorectal cancer: a comprehensive review. Metabolites. 2023;13(2):243. https://doi.org/10.3390/metabo13020243.
[69] Liu H, Johnston LJ, Wang F, Ma X. Triggers for the nrf2/are signaling pathway and its nutritional regulation: Potential therapeutic applications of ulcerative colitis. Int J Mol Sci. 2021;22(21):11411. https://doi.org/10.1177/17562848221138160.
[70] Laurindo LF, Santos AR, Carvalho AC, Bechara MD, Guiguer EL, Goulart RD, Vargas Sinatora R, Araújo AC, Barbalho SM. Phytochemicals and regulation of NF-kB in inflammatory bowel diseases: an overview of in vitro and in vivo effects. Metabolites. 2023;13(1):96. https://doi.org/10.3390/metabo13010096.
[71] Yu C, Wang D, Yang Z, Wang T. Pharmacological effects of polyphenol phytochemicals on the intestinal inflammation via targeting TLR4/NF-κB signaling pathway. Int J Mol Sci. 2022;23(13):6939. https://doi.org/10.3390/ijms23136939.
[72] Wang K, Mao T, Lu X, Wang M, Yun Y, Jia Z, Shi L, Jiang H, Li J, Shi R. A potential therapeutic approach for ulcerative colitis: targeted regulation of macrophage polarization through phytochemicals. Front Immunol. 2023;1(14):1155077. https://doi.org/10.3389/fimmu.2023.1155077.
[73] Du Y, Rong L, Cong Y, Shen L, Zhang N, Wang B. Macrophage polarization: an effective approach to targeted therapy of inflammatory bowel disease. Expert Opin Ther Targets. 2021;25(3):191-209. https://doi.org/10.1080/14728222.2021.1901079.
[74] do Nascimento RD, da FonsecaMachado AP, Galvez J, Cazarin CB, Junior MR. Ulcerative colitis: gut microbiota, immunopathogenesis and application of natural products in animal models. Life Sci. 2020;258: 118129. https://doi.org/10.1016/j.lfs.2020.118129.
[75] Abe H, Ishioka M, Fujita Y, Umeno A, Yasunaga M, Sato A, Ohnishi S, Suzuki S, Ishida N, Shichiri M, Yoshida Y. Yuzu (Citrus junos Tanaka) peel attenuates dextran sulfate sodium-induced murine experimental colitis. J Oleo Sci. 2018;67(3):335-44. https://doi.org/10.5650/jossess17184.
[76] Shin J, Song HY, Lee M. Sudachinoid-and ichangensin-type limonoids from Citrus junos downregulate pro-inflammatory cytokines. Int J Mol Sci. 2020;21(18):6963. https://doi.org/10.3390/ijms21186963.
[77] Kim SH, Shin EJ, Hur HJ, Park JH, Sung MJ, Kwon DY, Hwang JT. Citrus junos Tanaka peel extract attenuates experimental colitis and inhibits tumour growth in a mouse xenograft model. J Funct Foods. 2014;8:301-8. https://doi.org/10.1016/j.jff.2014.03.024.
[78] Kim Y, Wu AG, Jaja-Chimedza A, Graf BL, Waterman C, Verzi MP, Raskin I. Isothiocyanate-enriched moringa seed extract alleviates ulcerative colitis symptoms in mice. PLoS ONE. 2017;12(9): e0184709. https://doi.org/10.1371/journal.pone.0184709.
[79] Mohamed Husien H, Peng W, Su H, Zhou R, Tao Y, Huang J, Liu M, Bo R, Li J. Moringa oleifera leaf polysaccharide alleviates experimental colitis by inhibiting inflammation and maintaining intestinal barrier. Front Nutr. 2022;10(9):1055791. https://doi.org/10.3389/fnut.2022.1055791.
[80] Hong ZS, Xie J, Wang XF, Dai JJ, Mao JY, Bai YY, Sheng J, Tian Y. Moringa oleifera Lam. peptide remodels intestinal mucosal barrier by inhibiting JAK-STAT activation and modulating gut microbiota in colitis. Front Immunol. 2022;13: 924178. https://doi.org/10.3389/fimmu.2022.924178.
[81] Zhang Y, Peng L, Li W, Dai T, Nie L, Xie J, Ai Y, Li L, Tian Y, Sheng J. Polyphenol extract of Moringa oleifera leaves alleviates colonic inflammation in dextran sulfate sodium-treated mice. Evid Based Complement Altern Med. 2020. https://doi.org/10.1155/2020/6295402.
[82] Shao S, Wang D, Zheng W, Li X, Zhang H, Zhao D, Wang M. A unique polysaccharide from Hericium erinaceus mycelium ameliorates acetic acid-induced ulcerative colitis rats by modulating the composition of the gut microbiota, short chain fatty acids levels and GPR41/43 respectors. Int Immunopharmacol. 2019;1(71):411-22. https://doi.org/10.1016/j.intimp.2019.02.038.
[83] Wang D, Zhang Y, Yang S, Zhao D, Wang M. A polysaccharide from cultured mycelium of Hericium erinaceus relieves ulcerative colitis by counteracting oxidative stress and improving mitochondrial function. Int J Biol Macromol. 2019;125:572-9. https://doi.org/10.1016/j.ijbiomac.2018.12.092.
[84] Ren Y, Sun Q, Gao R, Sheng Y, Guan T, Li W, Zhou L, Liu C, Li H, Lu Z, Yu L. Low weight polysaccharide of Hericium erinaceus ameliorates colitis via inhibiting the NLRP3 inflammasome activation in association with gut microbiota modulation. Nutrients. 2023;15(3):739. https://doi.org/10.3390/nu15030739.
[85] Durmus A, Durmus I, Bender O, Karatepe O. The effect of Hericium erinaceum on the prevention of chemically induced experimental colitis in rats. Korean J Intern Med. 2021;36(Suppl 1):S44. https://doi.org/10.3904/kjim.2019.050.
[86] Gravina AG, Pellegrino R, Palladino G, Coppola A, Brandimarte G, Tuccillo C, Ciardiello F, Romano M, Federico A. Hericium erinaceus, in combination with natural flavonoid/alkaloid and B3/B8 vitamins, can improve inflammatory burden in Inflammatory bowel diseases tissue: an ex vivo study. Front Immunol. 2023. https://doi.org/10.3389/fimmu.2023.1215329.
[87] Shah TA, Parikh M, Patel KV, Patel KG, Joshi CG, Gandhi TR. Evaluation of the effect of Punica granatum juice and punicalagin on NFκB modulation in inflammatory bowel disease. Mol Cell Biochem. 2016;419:65-74. https://doi.org/10.1007/s11010-016-2750-x.
[88] Kamali M, Tavakoli H, Khodadoost M, Daghaghzadeh H, Kamalinejad M, Gachkar L, Mansourian M, Adibi P. Efficacy of the Punica granatum peels aqueous extract for symptom management in ulcerative colitis patients. A randomized, placebo-controlled, clinical trial. Complement Ther Clin Pract. 2015;21(3):141-6. https://doi.org/10.1016/j.ctcp.2015.03.001.
[89] Kalyankumarraju M, Puppala ER, Ahmed S, Kumar GJ, Tene K, Syamprasad NP, Sahu BD, Barua CC, Naidu VG. Zanthoxylum alatum Roxb. seed extract ameliorates stress aggravated DSS-induced ulcerative colitis in mice: plausible role on NF-κB signaling axis. J Ethnopharmacol. 2021;279: 114385. https://doi.org/10.1016/j.jep.2021.114385.
[90] Zaware B, Gilhotra R, Chaudhari SR. Potential of Mimosa pudica leaf in the treatment of ulcerative colitis in rat. Bangladesh J Pharmacol. 2018;13(3):241-7. https://doi.org/10.3329/bjp.v13i3.35648.
[91] Recinella L, Gorica E, Chiavaroli A, Fraschetti C, Filippi A, Cesa S, Cairone F, Martelli A, Calderone V, Veschi S, Lanuti P. Anti-inflammatory and antioxidant effects induced by Allium sativum L. extracts on an ex vivo experimental model of ulcerative colitis. Foods. 2022;11(22):3559. https://doi.org/10.3390/foods11223559.
[92] Owusu G, Obiri DD, Ainooson GK, Osafo N, Antwi AO, Duduyemi BM, Ansah C. Acetic acid-induced ulcerative colitis in Sprague Dawley rats is suppressed by hydroethanolic extract of Cordia vignei leaves through reduced serum levels of TNF-α and IL-6. Int J Chronic Dis. 2020;6:2020. https://doi.org/10.1155/2020/8785497.
[93] Adjouzem CF, Gilbert A, Mbiantcha M, Yousseu Nana W, Matah Marthe Mba V, Djuichou Nguemnang SF, Tsafack EG, Atsamo AD. Effects of aqueous and methanolic extracts of stem bark of Ansonia bonnie De wild (A polynucleate) on dextran sodium sulfate-induced ulcerative colitis in Wistar rats. Evid Based Complement Altern Med. 2020. https://doi.org/10.1155/2020/4918453.
[94] Qin W, Luo H, Yang L, Hu D, Jiang SP, Peng DY, Hu JM, Liu SJ. Rubia cordifolia L. ameliorates DSS-induced ulcerative colitis in mice through dual inhibition of NLRP3 inflammasome and IL-6/JAK2/STAT3 pathways. Heliyon. 2022. https://doi.org/10.1016/j.heliyon.2022.e10314.
[95] Gupta RA, Motiwala MN, Mahajan UN, Sabre SG. Protective effect of Sesbania grandiflora on acetic acid induced ulcerative colitis in mice by inhibition of TNF-α and IL-6. J Ethnopharmacol. 2018;12(219):222-32. https://doi.org/10.1016/j.jep.2018.02.043.
[96] Meurer MC, Mees M, Mariano LN, Boeing T, Somensi LB, Mariott M, Dos Santos AC, Longo B, França TC, Klein-Júnior LC, de Souza P. Hydroalcoholic extract of Tagetes erecta L. flowers, rich in the carotenoid lutein, attenuates inflammatory cytokine secretion and improves the oxidative stress in an animal model of ulcerative colitis. Nutr Res. 2019;66:95-106. https://doi.org/10.1016/j.nutres.2019.03.005.
[97] Almeer RS, Mahmoud SM, Amin HK, Moneim AE. Ziziphus spina-christi fruit extract suppresses oxidative stress and p38 MAPK expression in ulcerative colitis in rats via induction of Nrf2 and HO-1 expression. Food Chem Toxicol. 2018;1(115):49-62. https://doi.org/10.1016/j.fct.2018.03.002.
[98] Suluvoy JK, Sakthivel KM, Guruvayoorappan C, Grace VB. Protective effect of Averrhoa bilimbi L. fruit extract on ulcerative colitis in wistar rats via regulation of inflammatory mediators and cytokines. Biomed Pharmacother. 2017;91:1113-21. https://doi.org/10.1016/j.biopha.2017.05.057.
[99] Chen G, Yang Y, Liu M, Teng Z, Ye J, Xu Y, Cai X, Cheng X, Yang J, Hu C, Wang M. Banxia xiexin decoction protects against dextran sulfate sodium-induced chronic ulcerative colitis in mice. J Ethnopharmacol. 2015;26(166):149-56. https://doi.org/10.1016/j.jep.2015.03.027.
[100] Liu Y, Wang C, Wu J, Tan L, Gao P, Wu S, Tang D, Wang Q, Wang C, Li P, Liu J. Study on the comprehensive phytochemicals and the anti-ulcerative colitis effect of Saussurea pulchella. Molecules. 2023;28(4):1526. https://doi.org/10.3390/molecules28041526.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
